SAGE Therapeutics

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SAGE Therapeutics poised for Zuranolone launch in 2023, overcoming challenges

SAGE Therapeutics showcased strong financial performance and promising developments with Zuranolone, positioning the drug favorably for potential launch in 2023.
While facing challenges such as enrollment issues and DEA scheduling impacts, the company is leveraging opportunities in commercialization strategies and post-marketing studies to enhance Zuranolone's market presence.
Overall, Zuranolone's rapid and durable effects, alignment with current treatment practices, and targeted commercialization approach present a compelling opportunity for SAGE Therapeutics in the mental health treatment landscape.
By addressing challenges effectively and capitalizing on opportunities, SAGE Therapeutics is poised to make a significant impact in advancing treatments for mood disorders and improving patient outcomes.

Sage Therapeutics reports strong Q1 performance and eyes market expansion

Sage Therapeutics had a strong Q1 2023, focusing on brain health medicines and preparing for zuranolone's launch.
The company's financial position is solid, with growth opportunities in pipeline programs and proactive payer engagements.
Challenges include regulatory uncertainties and competition, but Sage is well-positioned to capitalize on market demand.
Opportunities lie in expanding product indications, proactive agreements with payers, and learning from competitors for strategic advantage.

SAGE Therapeutics to Launch Zurzuvae for Postpartum Depression, Overcomes FDA Setback

SAGE Therapeutics is poised to launch Zurzuvae for postpartum depression, leveraging its financial strength and clinical success. While facing challenges in MDD, the company is strategically adapting to focus on PPD and enhance operational efficiency. Opportunities lie in collaborations, pricing strategies, and addressing the significant market need for PPD treatments.

SAGE Therapeutics advances women's health with ZURZUVAE approval

SAGE Therapeutics navigates financial challenges while advancing innovative treatments for women's health.
ZURZUVAE's approval and commercialization plans present opportunities in a significant market segment.
Strategic focus on engagement, access, and market positioning key to ZURZUVAE's success.
Pipeline advancements and collaboration efforts position SAGE for future growth and impact.

SAGE Therapeutics excels with ZURZUVAE launch, poised for continued growth

SAGE Therapeutics had a strong performance in 2023, driven by the successful launch of ZURZUVAE and positive early market reception.
While facing challenges in data tracking and market competition, the company's focus on innovation and patient access presents growth opportunities.
With a robust pipeline and strategic initiatives in place, SAGE is well-positioned to maintain momentum and drive further success in the brain health space.

SAGE Therapeutics reports strong Zurzuvae launch amidst Parkinson's study setback

SAGE Therapeutics is navigating challenges from the PRECEDENT study while capitalizing on Zurzuvae's successful launch for PPD.
The company's pipeline progress and commitment to addressing cognitive disorders in neurodegenerative diseases showcase a strong focus on brain health.
Collaborative efforts with Biogen, strong payer coverage, and positive market feedback position Zurzuvae as a frontline treatment for PPD.
Strategic initiatives to educate prescribers, expand market reach, and refine study designs present promising growth opportunities for SAGE.

SAGE Therapeutics faces setbacks but sees success with ZURZUVAE in Q2

SAGE Therapeutics navigates setbacks with SAGE-324 study closure but sees success with ZURZUVAE in PPD treatment. Strong financial foundation and commitment to brain health initiatives position the company for future growth.

SAGE Therapeutics focuses on Zurzuvae for PPD treatment success

SAGE Therapeutics prioritizes Zurzuvae for PPD, showing strong revenue growth and prescription uptake
Challenges include discontinuation of certain programs and mixed results in clinical studies
Opportunities lie in focusing resources, upcoming study results, and strategic program ownership
Overall, SAGE's reorganization reflects a strategic shift towards maximizing Zurzuvae's potential

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Sage Therapeutics Inc. For Potential Securities Violations And Encourages Investors Who Have Incurred Losses To Initiate Discussions

LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Sage Therapeutics Inc Is Under The Schall Law Firm's Probe For Possible Securities Breaches And Investors With Losses Are Encouraged To Begin Conversations

LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Sage Therapeutics Inc Is Being Investigated By The Schall Law Firm For Potential Securities Violations And Investors With Losses Are Urged To Initiate Dialogue

NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Sage Therapeutics Inc Is Under Investigation By The Schall Law Firm For Potential Securities Violations, And Investors With Losses Are Encouraged To Initiate Dialogue

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Sage Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Investors With Losses Urged To Engage In Dialogue

Sage Therapeutics (SAGE) incurs a wider-than-expected second-quarter 2024 loss. Collaboration revenues from Zurzuvae drive year-over-year revenue growth.

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise

Sage Therapeutics, Inc., (NASDAQ:SAGE ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Ashley Kaplowitz - Vice President of Investor Relations and Capital Markets Barry Greene - Chief Executive Officer Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Salveen Richter - Goldman Sachs Anupam Rama - JPMorgan Yasmeen Rahimi - Piper Sandler Paul Matteis - Stifel Jay Olson - Oppenheimer. Ritu Baral - TD Cowen Brian Abrahams - RBC Capital Markets Laura Chico - Wedbush Securities David Hoang - Citigroup Tazeen Ahmad - Bank of America George Farmer - Scotiabank Vikram Purohit - Morgan Stanley Sumant Kulkarni - Canaccord Uy Ear - Muziho Douglas Tsao - H.C.

Sage Therapeutics, Inc., (SAGE) Q2 2024 Earnings Call Transcript

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.70 per share versus the Zacks Consensus Estimate of a loss of $1.68. This compares to loss of $2.68 per share a year ago.

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the second quarter ended June 30, 2024. “We are pleased with the strength of ZURZUVAE's early commercial launch performance and its positive, real-world impact on women suffering from PPD. Supported by several tailwinds, including increasing demand among a mix of providers,.

Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Little has gone right for the biotech in recent years.

Sage Therapeutics Stock Slides as Pipeline Thins

Sage Therapeutics said Wednesday its Biogen-partnered treatment for essential tremor failed in a study, leading Sage stock to collapse.

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails

Biogen

Companies halt development of neurological treatment, putting new pressure on Biogen's pipeline, analysts say.

Sage Therapeutics' stock dives as failed trial hits Biogen collaboration

LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Sage Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Investors With Losses Urged To Engage In Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Sage Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Investors With Losses Are Encouraged To Initiate Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Sage Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Investors With Losses Are Urged To Start Dialogues

Sage Therapeutics' (SAGE) Zurzuvae, approved for treating postpartum depression, holds an excellent commercial opportunity. The recent pipeline setbacks are, however, an overhang.

SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern

LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Sage Therapeutics Inc For Potential Securities Breaches And Encourages Investors Who Have Experienced Losses To Initiate Dialogues

LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Sage Therapeutics Inc Is Under Examination For Possible Securities Violations By The Schall Law Firm, Investors Who Have Suffered Losses Are Urged To Begin Conversations

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, July 31, 2024 at 4:30 p.m. ET to review second quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion.

Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024

LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Investors With Losses To Initiate Dialogue, Sage Therapeutics Inc Is Under Scrutiny For Potential Securities Violations

LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Sage Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Breaches Urging Investors With Losses To Start Conversation

LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Begins Investigation Into Sage Therapeutics Inc For Potential Securities Violations And Urges Investors With Losses To Initiate Conversation

LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Inquiry Into Sage Therapeutics Inc For Possible Securities Breaches Initiated By The Schall Law Firm Encouraging Investors With Losses To Start Dialogue

News for SAGE Therapeutics Stock (SAGE)